A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Launched by ASTELLAS PHARMA KOREA, INC. · Aug 22, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how well PADCEV Injection works for adults in South Korea who have urothelial cancer, which affects the lining of the bladder. The study will observe patients who are already receiving this treatment along with other medicines their doctors have prescribed. The main goal is to collect information about the outcomes of the treatment and any medical issues that might arise during the study period.
To participate, individuals must be adults receiving PADCEV Injection as part of their cancer care. They will be monitored for up to 48 weeks (about one year) after starting the treatment, and their medical records will be reviewed to track their health and cancer status. If a participant stops the treatment before the 48 weeks are up, their records will still be reviewed for one month after their last dose or until they begin a different cancer medication. This study is important for improving our understanding of how PADCEV Injection affects patients with urothelial cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who receive treatment with PADCEV Injection, according to the approved local label.
- Exclusion Criteria:
- • Patients with any contraindication for PADCEV Injection, according to the approved local label.
- • Patients who receive or are going to receive any investigational medicine during the observation period.
About Astellas Pharma Korea, Inc.
Astellas Pharma Korea, Inc. is a leading pharmaceutical company dedicated to advancing healthcare through innovative research and development. As a subsidiary of Astellas Pharma Inc., a global player in the biopharmaceutical industry, the company focuses on delivering novel therapies in areas such as oncology, urology, and immunology. Astellas Pharma Korea is committed to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals to address unmet medical needs. With a strong emphasis on scientific excellence and a patient-centered approach, Astellas Pharma Korea strives to enhance the quality of life for patients in South Korea and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Goyang Si, Gyeonggi Do, Korea, Republic Of
Suwon Si, Gyeonggi Do, Korea, Republic Of
Suwon Si, Gyeonggi Do, Korea, Republic Of
Jeonju Si, Jeonbuk Do, Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Daegu, , Korea, Republic Of
Incheon, , Korea, Republic Of
Jeollanam Do, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Central Contact
Study Director
Astellas Pharma Korea, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported